Predictive oncology inc. announces closing of $343.5 million in private placements to initiate digital asset treasury strategy

Investment creates the world's first strategic compute reserve  strategy complements predictive oncology's ai/ml-driven drug discovery and development activities pittsburgh, oct. 08, 2025 (globe newswire) -- predictive oncology inc. (“predictive oncology” or the “company”) (nasdaq: poai) today announced the closing of two previously announced private investment in public equity transactions (“pipes”) totaling approximately $343.5 million to support the company's adoption of a digital asset treasury strategy focused on ath, the native utility token of the aethir ecosystem. the company raised an aggregate of approximately $343.5 million in the pipes from the purchase and sale of (i) an aggregate of approximately 4.4 million shares of common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) for a purchase price of $11.6265 per share (the “offering price”) of common stock (or per pre-funded warrant in lieu thereof) for aggregate cash gross proceeds of approximately $50.8 million (the “cash pipe”), and (ii) pre-funded warrants to purchase up to approximately 14.9 million shares of common stock for a purchase price of $11.6165 per pre-funded warrant in exchange for approximately $292.7 million in notional value representing approximately $173.3 million in discounted value of in-kind contributions of locked and unlocked ath (the “crypto pipe”).
POAI Ratings Summary
POAI Quant Ranking